Mercury Diagnostic And Healthcare Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 27-10-2024
- Paid Up Capital ₹ 1.00 Cr
as on 27-10-2024
- Company Age 2 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 348.39%
(FY 2023)
- Profit 404.80%
(FY 2023)
- Ebitda 461.28%
(FY 2023)
- Net Worth 19.89%
(FY 2023)
- Total Assets -20.82%
(FY 2023)
About Mercury Diagnostic And Healthcare
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anita Khaitan, Parveen Jain, and Bal Agarwal serve as directors at the Company.
- CIN/LLPIN
U33119WB2022PLC251131
- Company No.
251131
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Jan 2022
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mercury Diagnostic And Healthcare?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anita Khaitan  | Director | 24-Jan-2022 | Current |
| Parveen Jain | Director | 24-Jan-2022 | Current |
| Bal Agarwal | Whole-Time Director | 24-Jan-2022 | Current |
Financial Performance and Corporate Structure Insights of Mercury Diagnostic And Healthcare.
Mercury Diagnostic And Healthcare Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 348.39% increase. The company also saw a substantial improvement in profitability, with a 404.8% increase in profit. The company's net worth Soared by an impressive increase of 19.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mercury Diagnostic And Healthcare?
In 2023, Mercury Diagnostic And Healthcare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Saswata Hospitality N Wellness LlpActive 5 years 2 months
Parveen Jain and Bal Agarwal are mutual person
- Fairplan Distributors Private LimitedActive 14 years 11 months
Parveen Jain and Bal Agarwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mercury Diagnostic And Healthcare?
Mercury Diagnostic And Healthcare has a workforce of 0 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mercury Diagnostic And Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mercury Diagnostic And Healthcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
